Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-27, Stock:NVS, The news for the past five days is as follows:
2019-02-20: NEWS1: AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review.NEWS2: AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review.NEWS3: AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review.NEWS4: The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering.NEWS5: Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review.NEWS6: Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review.
2019-02-21: NEWS1: Biogen stock down 1.2% after downgrade by Stifel.
2019-02-22: NEWS1: Novartis gene therapy would be cost effective up to $900,000 -U.S. group.NEWS2: Novartis gene therapy is cost effective at up to $900,000 -U.S. group.NEWS3: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for February 25, 2019.NEWS4: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for February 25, 2019.
2019-02-25: NEWS1: Big Pharma to testify in Senate drug pricing hearing.NEWS2: Novartis In-Licenses Rights to Heart Candidate From Ionis.NEWS3: Novartis In-Licenses Rights to Heart Candidate From Ionis.NEWS4: Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion.NEWS5: Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion.NEWS6: Novartis aims to pump up cardio business with Ionis deal.NEWS7: Novartis In-Licenses Rights to Heart Candidate From Ionis.NEWS8: Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion.NEWS9: Roche bets $4.3 bln on Spark in gene therapy move.NEWS10: Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners — What Drives Growth in Today's Competitive Landscape.NEWS11: Novartis licenses rights to RNA-targeting cardio drug from Ionis.NEWS12: [$$] Stocks to watch: Persimmon, General Electric, Centamin, Spark.
2019-02-26: NEWS1: What Wall Street Recommends for Amarin and Novavax.NEWS2: Biotech ETFs Jump on Roche-Spark Deal.NEWS3: Biotech ETFs Jump on Roche-Spark Deal.NEWS4: Biotech ETFs Jump on Roche-Spark Deal.NEWS5: Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA.NEWS6: Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA.NEWS7: Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA.NEWS8: Xencor Inc (XNCR) Q4 2018 Earnings Conference Call Transcript.

Answer: Decrease